(NASDAQ: KROS) Keros Therapeutics's forecast annual revenue growth rate of 768.53% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Keros Therapeutics's revenue in 2024 is $151,000.On average, 1 Wall Street analysts forecast KROS's revenue for 2024 to be $1,079,478,840, with the lowest KROS revenue forecast at $1,079,478,840, and the highest KROS revenue forecast at $1,079,478,840. On average, 3 Wall Street analysts forecast KROS's revenue for 2026 to be $3,634,965,081, with the lowest KROS revenue forecast at $2,479,203,069, and the highest KROS revenue forecast at $4,683,498,860.
In 2027, KROS is forecast to generate $8,185,831,974 in revenue, with the lowest revenue forecast at $1,244,639,103 and the highest revenue forecast at $12,736,770,833.